Cascadian Therapeutics (CASC)

[aries4747]

Oncothyreon Inc (NASDAQ:ONTY) Given Average Rating of “Buy” by Brokerages

http://www.financial-market-news.com/oncothyreon-inc-nasdaqonty-given-average-rating-of-buy-by-brokerages/899178/

February 29th, 2016 - By Samantha Reynolds - 0 comments

Oncothyreon logoOncothyreon Inc (NASDAQ:ONTY) has been given a consensus rating of “Buy” by the six analysts that are currently covering the company, AnalystRatingsNetwork.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.31.

Shares of Oncothyreon (NASDAQ:ONTY) traded down 6.538% during midday trading on Monday, hitting $0.972. The company had a trading volume of 503,788 shares. The company’s market capitalization is $92.27 million. Oncothyreon has a 12 month low of $0.90 and a 12 month high of $4.69. The company has a 50-day moving average of $1.30 and a 200-day moving average of $2.56.

Several equities research analysts have commented on ONTY shares. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Oncothyreon in a research note on Wednesday, December 9th. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 price objective on shares of Oncothyreon in a research note on Monday, January 11th. Jefferies Group reiterated a “buy” rating and set a $5.00 price objective on shares of Oncothyreon in a research note on Wednesday, December 9th. Finally, Zacks Investment Research lowered Oncothyreon from a “buy” rating to a “hold” rating in a research note on Tuesday, November 10th.

Oncothyreon Inc (NASDAQ:ONTY) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen.
12 Month Chart for NASDAQ:ONTY